Evaluation of Flibanserin: Science and Advocacy at the FDA. JAMA 2015 Sep 01;314(9):869-70
Date
07/07/2015Pubmed ID
26148201DOI
10.1001/jama.2015.8405Scopus ID
2-s2.0-84940749847 (requires institutional sign-in at Scopus site) 41 CitationsAuthor List
Gellad WF, Flynn KE, Alexander GCAuthor
Kathryn Eve Flynn PhD Vice Chair, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Advisory CommitteesBenzimidazoles
Consumer Advocacy
Depression
Drug Approval
Female
History, 21st Century
Humans
Libido
Sexual Dysfunctions, Psychological
United States
United States Food and Drug Administration